{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Kidney+Rejection+Transplant&page=6",
    "query": {
      "condition": "Kidney Rejection Transplant",
      "page": 6
    },
    "page_size": 10
  },
  "pagination": {
    "page": 6,
    "page_size": 10,
    "total_count": 210,
    "total_pages": 21,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Kidney+Rejection+Transplant&page=7&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Kidney+Rejection+Transplant&page=5&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T10:50:03.876Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00099736",
      "title": "Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Kidney Transplantation"
      ],
      "interventions": [
        {
          "name": "FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids",
          "type": "DRUG"
        },
        {
          "name": "FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids",
          "type": "DRUG"
        },
        {
          "name": "MMF 2 g + full-dose Neoral (FDN) + corticosteroids",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 696,
      "start_date": "2003-05-07",
      "completion_date": "2005-09-19",
      "has_results": false,
      "last_update_posted_date": "2017-08-22",
      "last_synced_at": "2026-11-15T10:50:03.876Z",
      "location_count": 42,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 36 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00099736"
    },
    {
      "nct_id": "NCT00782821",
      "title": "Randomized Trial of Induction Therapies in High Immunological Risk Kidney Transplant Recipients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Kidney Transplantation"
      ],
      "interventions": [
        {
          "name": "Rabbit Antithymocyte Globulin",
          "type": "DRUG"
        },
        {
          "name": "Velcade",
          "type": "DRUG"
        },
        {
          "name": "Rituxan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 40,
      "start_date": "2008-09",
      "completion_date": "2013-03",
      "has_results": true,
      "last_update_posted_date": "2016-01-20",
      "last_synced_at": "2026-11-15T10:50:03.876Z",
      "location_count": 2,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00782821"
    },
    {
      "nct_id": "NCT00346151",
      "title": "Belatacept to Prevent Organ Rejection in Kidney Transplant Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Renal Transplant"
      ],
      "interventions": [
        {
          "name": "Belatacept",
          "type": "DRUG"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        },
        {
          "name": "Anti-thymocyte globulin",
          "type": "DRUG"
        },
        {
          "name": "methylprednisolone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 5,
      "start_date": "2006-12",
      "completion_date": "2010-02",
      "has_results": true,
      "last_update_posted_date": "2017-04-21",
      "last_synced_at": "2026-11-15T10:50:03.876Z",
      "location_count": 2,
      "location_summary": "San Francisco, California • Atlanta, Georgia",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00346151"
    },
    {
      "nct_id": "NCT00896012",
      "title": "Kidney Biopsy Controlled Trial of Calcineurin Inhibitor Withdrawal",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Kidney Transplantation"
      ],
      "interventions": [
        {
          "name": "Kidney Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Rapamune (sirolimus/rapamycin)",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "University at Buffalo",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 58,
      "start_date": "2008-01",
      "completion_date": "2011-12",
      "has_results": true,
      "last_update_posted_date": "2023-08-14",
      "last_synced_at": "2026-11-15T10:50:03.876Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00896012"
    },
    {
      "nct_id": "NCT01895127",
      "title": "Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Antibody-mediated Rejection",
        "Humoral Rejection"
      ],
      "interventions": [
        {
          "name": "Eculizumab",
          "type": "DRUG"
        },
        {
          "name": "Immunoglobulin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Plasmapheresis",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 11,
      "start_date": "2013-11",
      "completion_date": "2016-04",
      "has_results": true,
      "last_update_posted_date": "2017-09-21",
      "last_synced_at": "2026-11-15T10:50:03.876Z",
      "location_count": 3,
      "location_summary": "San Francisco, California • Boston, Massachusetts • Ann Arbor, Michigan",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01895127"
    },
    {
      "nct_id": "NCT03289650",
      "title": "Extended Release Tacrolimus vs. Twice-Daily Tacrolimus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "End Stage Renal Disease",
        "Rejection of Renal Transplant"
      ],
      "interventions": [
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus Extended Release Oral Tablet [Envarsus]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lorenzo Gallon",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 29,
      "start_date": "2017-09-05",
      "completion_date": "2021-02-23",
      "has_results": true,
      "last_update_posted_date": "2023-04-10",
      "last_synced_at": "2026-11-15T10:50:03.876Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03289650"
    },
    {
      "nct_id": "NCT01953120",
      "title": "Mechanisms of Belatacept Effect on Alloimmunity and Antiviral Response After Kidney Transplantation (BMS IM 103-309)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Renal Transplant Rejection"
      ],
      "interventions": [
        {
          "name": "Belatacept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2013-10",
      "completion_date": "2021-04-21",
      "has_results": true,
      "last_update_posted_date": "2022-12-13",
      "last_synced_at": "2026-11-15T10:50:03.876Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01953120"
    },
    {
      "nct_id": "NCT00097968",
      "title": "Safety/Efficacy of Everolimus and Neoral® in Adult Cardiac Transplant Patients With Established Allograft Vasculopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Graft Rejection"
      ],
      "interventions": [
        {
          "name": "everolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": null,
      "start_date": "2004-08",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2010-07-12",
      "last_synced_at": "2026-11-15T10:50:03.876Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Minneapolis, Minnesota • New York, New York + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00097968"
    },
    {
      "nct_id": "NCT07219043",
      "title": "A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Microvascular Inflammation"
      ],
      "interventions": [
        {
          "name": "Felzartamab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "18 Years to 74 Years"
      },
      "enrollment_count": 81,
      "start_date": "2026-01-05",
      "completion_date": "2028-02-10",
      "has_results": false,
      "last_update_posted_date": "2026-11-05",
      "last_synced_at": "2026-11-15T10:50:03.876Z",
      "location_count": 25,
      "location_summary": "Loma Linda, California • Los Angeles, California • Orange, California + 19 more",
      "locations": [
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07219043"
    },
    {
      "nct_id": "NCT07805343",
      "title": "Extended Validation of Donor-derived Cell-free DNA in Kidney Transplant Recipients",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Rejection Acute Renal",
        "Rejection Chronic Renal",
        "Transplantation",
        "Kidney Rejection Transplant"
      ],
      "interventions": [
        {
          "name": "Donor-derived cell-free DNA",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Paris Translational Research Center for Organ Transplantation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 5000,
      "start_date": "2024-06-15",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-04",
      "last_synced_at": "2026-11-15T10:50:03.876Z",
      "location_count": 14,
      "location_summary": "Los Angeles, California • Tampa, Florida • Atlanta, Georgia + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07805343"
    }
  ]
}